NASDAQ:NKTR

Nektar Therapeutics Stock News

etoro logo Buy NKTR
*Your capital is at risk
$59.23
+0.670 (+1.14%)
At Close: Jun 03, 2026
Nektar Therapeutics (NASDAQ:NKTR ) Q1 2023 Earnings Conference Call May 9, 2023 5:00 PM ET Company Participants Vivian Wu - Investor Relations Howard Robin - President and Chief Executive Officer Jona
Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include Disney (DIS), Casey's General Stores (CASY), OpGen (OPGN), Accelerate Diagnostics (AXDX) and Nekt
Nektar Therapeutics shares rallied late Monday after the biotech drug maker said it was cutting staff by 60% in San Francisco, where the company is based, and shifting its focus to immunology drugs in
Finding the best pharma stocks to sell can be an all-or-nothing kind of business. If you score on a company making a breakthrough in a new drug or treatment, the rewards can be extreme, but investing
Here we discuss some reasons why investing in Nektar Therapeutics (NKTR) stock now is a good idea despite its several pipeline setbacks.
Penny stocks, the stock market game & what traders are watching this week. The post 4 Penny Stocks To Watch If You're Playing The “Stock Market Game” appeared first on Penny Stocks to Buy, Picks,

9 Hot Penny Stocks Under $0.99 To Watch Right Now

11:48am, Wednesday, 05'th Apr 2023
Penny stocks to watch under $1 The post 9 Hot Penny Stocks Under $0.99 To Watch Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Penny stocks under $1 to watch right now. The post 6 Hot Penny Stocks To Buy For Under $1 Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Nektar (NKTR) reported earnings 30 days ago. What's next for the stock?

Nektar (NKTR) Upgraded to Buy: Here's Why

01:45pm, Friday, 24'th Mar 2023
Nektar (NKTR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Small-cap stocks, in general, are more domestic in nature, and this protects them from geopolitical and foreign exchange risks.
Nektar Therapeutics (NASDAQ: NKTR ) stock is taking a beating on Friday following the release of Phase 2 clinical trial data. This Phase 2 study had Nektar Therapeutics testing the effectiveness of re
Shares of Nektar Therapeutics NKTR, -1.66% plunged more than 30% in the extended session Thursday after the biopharma company reported that a study did not meet goals and that partner Eli Lilly & Co.
Few investors can hit all the year's best S&P 500 stocks. But some were unlucky enough to own big stakes of the worst.
Once bearish sentiment ends, good quality biotech stocks will bounce back, but Nektar Therapeutics probably won't. Funds continue to dwindle while projects are far from commercialization stage.
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE